Development of anti-TNF therapy for rheumatoid arthritis

By M. Feldmann. Nature reviews. Immunology, 2002

727 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/c57f06e81876a35e499d223e1cdc22c80fbf6e43

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Hematology

In Rheumatology

Citations in the corpus

Emerging Role of Endosomal Toll-Like Receptors in Rheumatoid Arthritis (2013, background): “The longest standing are those targeting TNF; the anti-TNF antibodies infliximab, adalimumab, and golimumab, the polyethylene glycol-linked mAb fragment certolizumab pegol, and the soluble TNF receptor-2-IgG-Fc fusion protein etanercept (13, 14).”
The alpha7 nicotinic acetylcholine receptor as a pharmacological target for inflammation (2007, background): “This effect is illustrated by the studies indicating that neutralizing pro-inflammatory cytokines (monoclonal anti-TNF antibodies, IL-1 receptor antagonists and TNF-receptor fusion proteins) have proven to be successful in inflammatory conditions such as rheumatoid arthritis, Crohn’s disease, ankylo”
Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. (2011, background): “For example, mAbs that target TNF-α are now the standard treatment for patients with chronic inflammatory arthritis, and alternative therapies, which target other cytokines, are also emerging in routine clinical practice (1, 2).”
Tumour necrosis factor and cancer (2009, background): “This led to the development of antagonists of its action that revolutionized the treatment of rheumatoid arthritis and other inflammatory disease”
Compromised Function of Regulatory T Cells in Rheumatoid Arthritis and Reversal by Anti-TNFα Therapy (2004, background): “) play in the induction and maintenance of this disease is well documented (15).”
IL-23 drives a pathogenic T cell population that induces autoimmune inflammation (2005, background): “The role of TNF in chronic inflammatory diseases is well recognized (36).”
Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. (2008, background): “Acute-phase reactants, such as CRP, serum amyloid A and fibrinogen, are considered the hallmarks of systemic inflammation.”
The gut microbiota regulates bone mass in mice (2012, background): “TNFa is one of the critical cytokines in the pathogenesis of RA, as shown bymany gain- and loss-of-function genetic models, as well as by the clinical efficacy of anti-TNFa therapy.((49,50)) Patients with psoriatic arthritis and mice with TNFa-induced arthritis have increased numbers of circulating ”
TNF-α in promotion and progression of cancer (2006, methodology): “Inhibitors of TNF-α, in particular, have been used successfully in over half a million patients worldwide [11].”
Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS) (2011, background): “It has also made its way in human disease where it has revolutionized the treatment of rheumatoid arthritis (RA), for example, where anti-tumour necrosis factor (TNF) biologicals are now in well-established use and have made a great impact on the quality of life and the prevention of late complicati”
Chronic Adipose Tissue Inflammation Linking Obesity to Insulin Resistance and Type 2 Diabetes (2020, background): “For instance, TNF-α neutralizing antibodies have been shown to be effective for the treatment of many other inflammatory diseases, and some patients have shown slight improvements in glycemic control (Ofei et al., 1996; Feldmann, 2002; Reilly et al., 2013).”